Global Burden of Disease Study

JOURNAL OF MEDICAL INTERNET RESEARCH | CAN ARTIFICIAL INTELLIGENCE BE USED TO DIAGNOSE INFLUENZA?

Retrieved on: 
星期二, 三月 28, 2023
Telehealth, Medicine, Use, Pharynx, Journal of Medical Internet Research, Disease, Deep learning, COVID-19, Research, Publication, Epidemic, Report, Pandemic, Hospital, Journal, MD, Patient, Polymerase chain reaction, Physician, Risk, Diagnosis, AI, PCR, Global Burden of Disease Study, Vaccine, Medical imaging, Medical device

TORONTO and PHILADELPHIA, March 28, 2023 /PRNewswire/ -- JMIR Publications published "Examining the Use of an Artificial Intelligence Model to Diagnose Influenza: Development and Validation Study" in the Journal of Medical Internet Research, which reported that it may be possible to diagnose influenza infection by applying deep learning to pharyngeal images given that influenza primarily infects the upper respiratory system.

Key Points: 
  • These authors aimed to develop a deep learning model to diagnose influenza infection using pharyngeal images and clinical information.
  • In the training stage, the authors developed a diagnostic prediction artificial intelligence (AI) model based on deep learning to predict polymerase chain reaction (PCR)-confirmed influenza from pharyngeal images and clinical information.
  • This process led to the development of the first AI model that can accurately diagnose influenza.
  • Dr Okiyama and the research team concluded in their JMIR Publications Research Article , "we developed the first AI-assisted diagnostic camera for influenza and prospectively validated its high performance.

Study of dietary and nutrition recommendations from worldwide clinical practice guidelines finds close alignment on benefits of plant food groups

Retrieved on: 
星期一, 三月 27, 2023
Tufts University, Nutrition, ST, Obesity, Nut, Prevalence, Seed, Public, Cardiovascular disease, Cancer, Type 2 diabetes, Grain boundary strengthening, Vegetable, Fruit, MS, Harvard Medical School, Chronic obstructive pulmonary disease, Internet, ACLM, Death, Patient, Physician, Advances in Nutrition, Overweight, Confusion, Conditional sentence, Knowledge, Sodium, Health, American College, Tobacco smoking, Global Burden of Disease Study, Dietary supplement, Nursing, Doctor of Philosophy, MD, Policy, Research

ST. LOUIS, Mo., March 27, 2023 /PRNewswire-PRWeb/ -- The results of a study published March 23 in "Advances in Nutrition" that compared dietary and nutrition recommendations from dozens of clinical practice guidelines around the world for treating, managing and preventing major chronic diseases should increase clinician confidence on recommending consumption of fruits, vegetables, legumes and whole grains.

Key Points: 
  • Dietary patterns, food groups and food components were of primary interest in the study, with macronutrient and micronutrient recommendations a secondary interest.
  • For food groups, nearly three quarters of clinical practice guidelines recommended including or increasing intake of vegetables, which was the highest percentage of any food group.
  • To the authors' knowledge, this was the first study to compare dietary recommendations across current clinical practice guidelines for multiple major chronic diseases.
  • We hope the results of this study will assist physicians in developing the foundation of knowledge needed to achieve those outcomes."

Global Digital Dose Inhalers Market Report to 2027: North America is Expected to Dominate the Market - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 21, 2023
Pharmaceutical, Health, Medical Devices, Inhaler, COPD, NORTH, Smoker, Asthma, MDI, Prevalence, DPI, Administration, Greenhouse gas, Dry-powder inhaler, Organization, Economy, Chlorofluorocarbon, Medicine, AMERICA, Chronic obstructive pulmonary disease, Death, Isocyanate, Digital technology, Azerbaijan and Organization for Economic Co-operation, Roflumilast, Metered-dose inhaler, Dust, Cystic fibrosis, Global Burden of Disease Study, Growth, WHO, Air pollution, CO2, DIGITAL, World Health Organization, Pharmaceutical industry, Geography

Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.

Key Points: 
  • Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.
  • One of the key aspect for driving the digital dose inhalers market is the rising prevalence of various respiratory disorders globally.
  • DIGITAL DOSE INHALERS MARKET SEGMENT ANALYSIS:
    Digital Dose Inhalers Market by Product Type (Dry Powder Inhalers and Metered Dose Inhalers), Application (Chronic Obstructive Pulmonary Disease, Asthma, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
  • NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL DIGITAL DOSE INHALERS MARKET:
    Among all the regions, North America is expected to dominate the global digital dose inhalers market in the year 2021 and is expected to do the same during the forecast period from 2022-2027.

Olympus to Acquire Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd

Retrieved on: 
星期五, 二月 24, 2023
Stenosis, Cancer, Colon, Endoscopy, Anatomy, Jaundice, Ageing, Duodenum, Acquisition, Risk, Gastrointestinal disease, Standard of care, Global Burden of Disease Study, Stent, Patient, Mechanical, Investment, MM, Esophagus, Self-expandable metallic stent, Gallbladder, Restenosis, Cholangiocarcinoma, Biliary tract, JPY, International, Sale, Metallic, Bile, Disease, Olympus, Pharmaceutical industry, Medical imaging, Fine chemical, Software, GI

Taewoong Medical, a leading manufacturer of GI stents, offers a variety of medical devices including metallic stents designed for biliary tract, esophagus, colon, and duodenum treatments[5].

Key Points: 
  • Taewoong Medical, a leading manufacturer of GI stents, offers a variety of medical devices including metallic stents designed for biliary tract, esophagus, colon, and duodenum treatments[5].
  • "Taewoong Medical has developed a full portfolio of GI metal stents that will immediately enhance our already robust offering of GI devices.
  • Kyong-min Shin, President and CEO of Taewoong Medical stated, "For over three decades, Taewoong Medical has been a leading manufacturer of GI stents, renowned for its innovative technology and diverse product range.
  • Moving forward together with Olympus, Taewoong Medical will focus its capabilities to provide medical professionals and patients with superior products and services through continuous investment in R&D and manufacturing technology."

Joint Pain Injections Global Market Report 2022: Significant Rise in Tenosynovitis and Prolonged Physical Activity Fuels Demand - ResearchAndMarkets.com

Retrieved on: 
星期一, 一月 30, 2023
Pharmaceutical, Health, Other Health, Shoulder, Joint, Accident, Allergan, Tenosynovitis, Disease, Obesity, Hyaluronic acid, Athlete, Synovial fluid, Lubrication, Shock, Pfizer, Research, DSM-IV codes, Disability-adjusted life year, Arthralgia, Organic acid, Global Burden of Disease Study, Growth, Knee, Injection, Prevalence, Osteoarthritis, Pharmaceutical industry

Hyaluronic acid injection is reigning the injections segment for joint pain injections market.

Key Points: 
  • Hyaluronic acid injection is reigning the injections segment for joint pain injections market.
  • Currently knee & ankle joints are dominating the joint segment for joint pain injections market.
  • The major factors associated with its market growth are significant rise in tenosynovitis and prolonged physical activity.
  • North America with a share of 34% is leading the regional segment for joint pain injections market.

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Retrieved on: 
星期四, 一月 12, 2023
Biotechnology, Neurology, Mental Health, Health, Clinical Trials, Anxiety disorder, Inc., Scientific Reports, Disease, Comorbidity, SSRI, Injury, Psychedelic drug, Depression, Anxiety, McIntyre, DMT, Quality of life, Safety, NEO, Lancet, NYSE, Global Burden of Disease Study, MDD, Current Opinion (Lippincott Williams & Wilkins), GAD, Generalized anxiety disorder, Patient, IV, Therapy, Prevalence, Recurrence, Human, Pharmaceutical industry, Birth control

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics® today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004.

Key Points: 
  • Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics® today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004.
  • "Based on preclinical data, CYB004 has shown promise in treating anxiety disorders.
  • Over 40 million adults in the U.S. (19.1% of the total U.S. population) have an anxiety disorder.1
    Additional Facts about Anxiety and Generalized Anxiety Disorder:
    Among psychiatric disorders, GAD and MDD are the leading contributors to global disability.
  • Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder.

Click Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Episodic Migraine

Retrieved on: 
星期五, 十二月 16, 2022
Health, Technology, Neurology, Health Technology, Software, Pharmaceutical, Highs in the Mid-Sixties, Volume 17, Impact, Major depressive disorder, Neurology, Clinical trial, Employment, The Lancet, Geisel School of Medicine, Atopic dermatitis, CNS, Prevalence, MS, Verily, Food, Chronic pain, FDA, Breakthrough, ACS, Headache, Injury, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Digital, Journal, Doctor of Philosophy, Global Burden of Disease Study, Disease, MDD, Acute coronary syndrome, MD, Disability, Ageing, CNI, Dynamo, Research, GBD, Therapy, Standard of care, FAAN, Patient, Dartmouth, Pharmaceutical industry, Medical device, Medical imaging, Migraine, Lancet, Head, Schizophrenia, Obesity

Click Therapeutics, Inc. (Click), a leader in Digital Therapeutics as prescription medical treatments, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132.

Key Points: 
  • Click Therapeutics, Inc. (Click), a leader in Digital Therapeutics as prescription medical treatments, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132.
  • Clicks CT-132 prescription digital therapeutic is under development as an adjunctive preventive treatment for episodic migraine in patients aged 18 years and older.
  • The program is designed to expedite the development and review of medical devices meeting Breakthrough criteria in the United States.
  • We are thrilled to receive this Breakthrough designation as it will facilitate collaborative discussions with the FDA and help expedite the process of bringing a first-in-class migraine digital therapeutic to patients, said Austin Speier, Chief Strategy Officer of Click Therapeutics.

Global Biostimulants Market Size to Reach USD 9.25 Billion in 2030 | Emergen Research

Retrieved on: 
星期三, 十二月 14, 2022
Water, Fruit, BASF SE, Horticulture, Chitin, Food, EBIC, Forestry, SE, Plant, FMC Corporation, Global Burden of Disease Study, Recycling, Royal commission, Sewage, Salinity, Farmer, Soil, UPL, Agriculture, Research, Industrial waste, Vegetable, Nutrient, Chitosan, European Commission, Bandini s.p. 1000, Death, Biomass, Growth, BASF, Health, Food industry, USD, Risk, Fertilizer, Environmental remediation, Biostimulation, EU

VANCOUVER, BC, Dec. 14, 2022 /PRNewswire/ -- The Biostimulants market size reached USD 3.28 Billion in 2021 and is expected to register a CAGR of 12.1% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, BC, Dec. 14, 2022 /PRNewswire/ -- The Biostimulants market size reached USD 3.28 Billion in 2021 and is expected to register a CAGR of 12.1% during the forecast period, according to latest analysis by Emergen Research .
  • In the upcoming years, market growth is expected to be greatly aided by these governmental initiatives.
  • Biostimulants are a class of organic compounds that can increase plant growth and nutrient uptake while lowering the need for chemical fertilizers.
  • The Biostimulants market is expected to register a CAGR of 12.1% over the forecast period and revenue is projected to increase from USD 3.28 Billion in 2021 to USD 9.25 Billion in 2030.

Global Biostimulants Market Size to Reach USD 9.25 Billion in 2030 | Emergen Research

Retrieved on: 
星期三, 十二月 14, 2022
Water, Fruit, BASF SE, Horticulture, Chitin, Food, EBIC, Forestry, SE, Plant, FMC Corporation, Global Burden of Disease Study, Recycling, Royal commission, Sewage, Salinity, Farmer, Soil, UPL, Agriculture, Research, Industrial waste, Vegetable, Nutrient, Chitosan, European Commission, Bandini s.p. 1000, Death, Biomass, Growth, BASF, Health, Food industry, USD, Risk, Fertilizer, Environmental remediation, Biostimulation, EU

VANCOUVER, BC, Dec. 14, 2022 /PRNewswire/ -- The Biostimulants market size reached USD 3.28 Billion in 2021 and is expected to register a CAGR of 12.1% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, BC, Dec. 14, 2022 /PRNewswire/ -- The Biostimulants market size reached USD 3.28 Billion in 2021 and is expected to register a CAGR of 12.1% during the forecast period, according to latest analysis by Emergen Research .
  • In the upcoming years, market growth is expected to be greatly aided by these governmental initiatives.
  • Biostimulants are a class of organic compounds that can increase plant growth and nutrient uptake while lowering the need for chemical fertilizers.
  • The Biostimulants market is expected to register a CAGR of 12.1% over the forecast period and revenue is projected to increase from USD 3.28 Billion in 2021 to USD 9.25 Billion in 2030.

Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder

Retrieved on: 
星期四, 十二月 1, 2022
Mental Health, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Mental health, Psychiatry, Science, Commercialization, Regulation of tobacco by the U.S. Food and Drug Administration, Global Burden of Disease Study, Sunovion, Grammatical mood, Cardiology, MDD, Algorithm, Patient, Heart, Education, Creativity, Psychology, Maintenance, Medicine, Medication, OAPI, Health, Oncology, Trial of the century, FDA, Food, SUNOVION, Disease, Depression, Tuberculosis, The Lancet, Research, MADRS, TAAR1, Safety, Schizophrenia, Breakthrough therapy, Multimedia, Mood disorder, Investment, Disability, Nephrology, Pharmaceutical industry, Fine chemical

Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.

Key Points: 
  • Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.
  • Ulotaront was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in 2019.
  • Its also the first TAAR1 agonist to enter into a Phase 2/3 clinical study as an adjunctive therapy for MDD.
  • Major depressive disorder is a chronic debilitating disease characterized by symptoms that last at least two weeks causing significant functional impairment.